Literature DB >> 12617916

Structure-based design of thioether-bridged cyclic phosphopeptides binding to Grb2-SH2 domain.

Peng Li1, Megan L Peach, Manchao Zhang, Hongpeng Liu, Dajun Yang, Marc Nicklaus, Peter P Roller.   

Abstract

A series of phosphotyrosine containing cyclic peptides was designed and synthesized based upon the phage library derived cyclopeptide, G1TE. Considering the type-I beta-turn feature of peptidic ligand binding to Grb2 SH2 domain, we introduce alpha,alpha-disubstituted cyclic amino acid, Ach, into the 4th position of the cyclic peptide to induce a local right handed 3(10) helical conformation. In order to stabilize the favorable binding conformation, the bulky and hydrophobic amino acids, neopentylglycine (NPG) and phenylalanine, were introduced into the 8th and 2nd positions of the peptide ligand, respectively. To facilitate the sidechain of pTyr3 reaching into the phosphotyrosine binding pocket, a less bulky alanine was preferred in position 1. Based upon these global modifications, a highly potent peptide ligand 12 was discovered with an IC(50)=1.68 nM, evaluated by ELISA binding essay. Ligand 12 is at least 10(5) more potent than the lead peptide, termed G1TE.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12617916     DOI: 10.1016/s0960-894x(03)00015-5

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Thermodynamic and Structural Effects of Macrocyclization as a Constraining Method in Protein-Ligand Interactions.

Authors:  John E Delorbe; John H Clements; Benjamin B Whiddon; Stephen F Martin
Journal:  ACS Med Chem Lett       Date:  2010-11-11       Impact factor: 4.345

2.  Discovery of thioether-bridged cyclic pentapeptides binding to Grb2-SH2 domain with high affinity.

Authors:  Sheng Jiang; Chenzhong Liao; Lakshman Bindu; Biaolin Yin; Karen W Worthy; Robert J Fisher; Terrence R Burke; Marc C Nicklaus; Peter P Roller
Journal:  Bioorg Med Chem Lett       Date:  2009-03-29       Impact factor: 2.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.